

Chris Simpson and Team Advise Sanacor Inc. on its Collaboration Agreement with Chemify to Develop Small Molecule

(February 27, 2026) Polsinelli congratulates its client Sanacor (www.sanacor.com), on its complex collaboration with Chemify to accelerate the development of small-molecule therapies for Cardiometabolic diseases.

Sanacor Inc. is a biotechnology company developing therapies that target mitochondrial dysfunction in cardiometabolic diseases. The collaboration brings together Chemify's Chemputation technology for novel, small-molecule design and synthesis with Sanacor's deep biological expertise in cardiometabolic disease.

The economic terms of the collaboration are confidential and non-public. More information about the collaboration can be obtained here: [announcement](#).

The Polsinelli Venture Capital and Emerging Growth Companies team involved in the deal included Chris Simpson and Izzy Drake.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,200 attorneys in over 25 offices nationwide. Recognized as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients' expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight, offering comprehensive corporate, transactional, litigation and regulatory services with a focus on health care, real estate, finance, technology, private equity and life sciences. Polsinelli PC, Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.